Sponsors / CMPX
CMPX

Compass Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
2Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Compass TherapeuticsPhase 2, Phase 3Active not recruiting2027-08-31Estimated
A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742Compass TherapeuticsPhase 2Completed2025-05-15Actual

Latest recorded trial changes

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943 · Compass Therapeutics

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

150 participants (planned)

+ After

168 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jul 2025

+ After

21 Jan 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source